Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The Investigators plan to study the innate and adaptive immune response, the inflammatory response, and associated complications such as complement activation and neurological damage in SARS-Cov-2 infected individuals. Patients with mild, moderate and severe COVID-19 disease will be enrolled.
Description: Measurement of cytokine concentration (pg/ml) in serum (IL-6, IL-8, IL-1b,TNF-alpha)
Measure: Cytokine response to SARS-Cov-2 Time: At enrollmentDescription: Measurement of cytokine concentration (pg/ml) in serum (IL-6, IL-8, IL-1b,TNF-alpha)
Measure: Cytokine response to SARS-Cov-2 Time: 28 days (+/-7) after enrollmentDescription: Measurement of HLA-DR expression on CD14+ cells (flowcytometry)
Measure: Innate immune response to SARS-Cov-2 Time: At enrollmentDescription: Measurement of HLA-DR expression on CD14+ cells (flowcytometry)
Measure: Innate immune response to SARS-Cov-2 Time: 3 days after enrollmentDescription: Measurement of HLA-DR expression on CD14+ cells (flowcytometry)
Measure: Innate immune response to SARS-Cov-2 Time: 5 days after enrollmentDescription: Measurement of neutralizing SARS-Cov-2 antibody concentrations (plaque reduction assay)
Measure: Humoral immune response Time: At enrollmentDescription: Measurement of frequencies of SARS-Cov-2 specific T-cells (ELISPOT assay)
Measure: Cell mediated immune response Time: At enrollmentDescription: Measurement of frequencies of SARS-Cov-2 specific T-cells (ELISPOT assay)
Measure: Cell mediated immune response Time: 28 days (+/-7) after enrollmentDescription: Measurement of neurofilament light chains in serum (on ELLA platform; Protein Simple, Bio-techne)
Measure: Neurological damage Time: At enrollmentDescription: Measurement of neurofilament light chains in serum (on ELLA platform; Protein Simple, Bio-techne)
Measure: Neurological damage Time: 28 days (+/-7) after enrollmentDescription: Measurement of factor B, factor H, factor I, C3a, C4a, C5a, SC5b9
Measure: Complement activation Time: At enrollmentDescription: Measurement of factor B, factor H, factor I, C3a, C4a, C5a, SC5b9
Measure: Complement activation Time: 28 days (+/-7) after enrollmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports